计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| O414061-5mg |
5mg |
期货 ![]() |
| |
| O414061-25mg |
25mg |
期货 ![]() |
| |
| O414061-100mg |
100mg |
现货 ![]() |
|
| 别名 | 奥格列汀 | 奥格列汀(MK-3102) |
|---|---|
| 英文别名 | AC-28992 | J-690074 | MFCD22573261 | (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine | AKOS025289528 | CHEBI:134735 | (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Omarigliptin (MK-3102) |
| 生化机理 | 奥马列汀(MK-3102)是一种 DPP-4 竞争性可逆抑制剂(IC50 = 1.6 nM,Ki = 0.8 nM)。它对所有测试过的蛋白酶都具有高度选择性(IC50 > 67 μM),包括 QPP、FAP、PEP、DPP8 和 DPP9,并具有微弱的离子通道活性(IKr、Caγ1.2 和 Naγ1.5 的 IC50 > 30 μM)。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 二肽基肽酶 IV 抑制剂 |
| 产品介绍 |
Information Omarigliptin (MK-3102) Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5). Targets DPP-4 (Cell-free assay) 1.6 nM In vitro Omarigliptin is a potent inhibitor of DPP-4 and is highly selective over other proteases tested (IC50 > 67 μmol/L) and has weak ion channel activity (IC50 > 30 μmol/L at IKr, Caγ1.2, and Naγ1.5). Additionally, an IC50 > 10 μmol/L was obtained in all assays in an expansive selectivity counterscreen (168 radioligand binding or enzymatic assays). Omarigliptin binds rapidly and competitively to the active site of DPP-4, a process that is reversible and highly selective, and thus leads to increased levels of insulin and decreased levels of Glukagon under hyperglycaemic conditions. In vivo In lean mice, when orally administered 1 h prior to dextrose challenge in an oral glucose tolerance test (OGTT), it significantly reduced blood glucose excursion in a dose-dependent manner from 0.01 mg/kg (7% reduction in glucose AUC) to 0.3 mg/kg (51% reduction). the administration of omarigliptin dose-dependently increases plasma concentrations of active GLP-1. The pharmacokinetics of omarigliptin in male Sprague−Dawley rat and beagle dog are characterized by a low plasma clearance (0.9−1.1 mL/min/kg), a volume of distribution at steady state of 0.8−1.3 L/kg, and a long terminal half-life (∼11−22 h). The oral bioavailability of omarigliptin is good in both dogs and rats (∼100%). Omarigliptin is well-tolerated over the duration of the study, with no mortality or physical signs noted. Following the administration of a single oral dose of 25 mg in volunteers, omarigliptin was rapidly absorbed, with peak concentrations (Cmax) of 750 nmol/L reached within 1 h (Tmax). Bioavailability was estimated to be ≥74 %. |
| 纯度 | ≥99% |
| ALogP | 0.3 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770682 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine |
| INCHI | 1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1 |
| InChi Key | MKMPWKUAHLTIBJ-ISTRZQFTSA-N |
| Smiles | CS(=O)(=O)N1C=C2CN(CC2=N1)C3CC(C(OC3)C4=C(C=CC(=C4)F)F)N |
| Isomeric SMILES | CS(=O)(=O)N1C=C2CN(CC2=N1)[C@@H]3C[C@@H]([C@H](OC3)C4=C(C=CC(=C4)F)F)N |
| 分子量 | 398.43 |
| Reaxy-Rn | 47912824 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=47912824&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 79 mg/mL (198.27 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| 分子量 | 398.400 g/mol |
| XLogP3 | 0.300 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 398.122 Da |
| 单同位素质量Monoisotopic Mass | 398.122 Da |
| 拓扑极表面积Topological Polar Surface Area | 98.800 Ų |
| 重原子数Heavy Atom Count | 27 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 649.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 3 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS05, GHS07, GHS08 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H315: 引起皮肤刺激 H317: 可能引起皮肤过敏反应 H318: 造成严重的眼睛损伤 H334: 吸入可能引起过敏或哮喘病症状或呼吸困难 H335: 可能引起呼吸道刺激 H341: 怀疑引起遗传缺陷 H361: 怀疑破坏生育力或未出生的孩子 H370: 对器官造成损害 H413: 可能对水生生物造成长期的有害影响 |
| 预防措施声明 |
P201: 使用前获取特殊说明 P202: 在阅读并理解所有安全预防措施之前,不要进行操作。 P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P271: 仅在室外或通风良好的地方使用。 P272: 被污染的工作服不允许离开工作场所 P273: 避免释放到环境中。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P310: 立即致电解毒中心或医生。 P321: 特殊处理(请参阅此标签上的...)。 P362: 脱下污染的衣服并洗净后再使用。 P302+P352: 如皮肤沾染:用水充分清洗。 P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 P333+P313: 如发生皮肤刺激或皮疹:求医/就诊。 P403: 存放在通风良好的地方。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | O414061 |
| 1. Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe JT, Scapin G, Gao YD, Yan Y, Krueger D et al.. (2014) Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.. J Med Chem, 57 (8): (3205-12). [PMID:24660890] |